Exact Sciences Shares Surge on Abbott's $21 Billion Acquisition Deal
Shares of Exact Sciences (NASDAQ:EXAS) surged on November 20, 2025, following the announcement that it would be acquired by Abbott Laboratories in an all-cash transaction valued at $21 billion. The news sent the stock price up by 17.25%, an increase of $14.87 to close at $101.05.
During the trading session, the stock reached a high of $101.87, which also marked a new 52-week high. The day's low was $100.95. Investor interest was significant, with trading volume reaching 53.63 million shares. The stock's lowest price over the past year was $38.81. The rally increased Exact Sciences' market capitalization to approximately $19.15 billion.
The acquisition news prompted a price target update from Robert W. Baird analyst Catherine Ramsey Schulte, who set a target of $105 for EXAS. At the time of the report, the stock was trading at $101.34, suggesting a potential upside of 3.61%.
Exact Sciences is a key company in the molecular diagnostics industry, focusing on cancer screening products. The acquisition by Abbott Laboratories is seen as a strategic move to expand its capabilities and market presence. More information about the company's background can be found in its history and mission and its corporate vision. For further details on its standing, see its financial health and investor profile.
Exact Sciences Corporation (EXAS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.